Naureen Quibria

Stock Analyst at Capital One

(n/a)

# 4,540

Out of 4,931 analysts

9

Total ratings

11.11%

Success rate

-45.17%

Average return

Main Sectors:

Top Industries:

Stocks Rated by Naureen Quibria

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	BMEA Biomea Fusion	Initiates: Overweight	$25	$1.63	+1,433.74%	1	Aug 29, 2024
	IMMP Immutep	Initiates: Overweight	$10	$1.81	+452.49%	1	May 17, 2024
	ERAS Erasca	Initiates: Overweight	$8	$1.46	+447.95%	1	Mar 11, 2024
	CARM Carisma Therapeutics	Initiates: Overweight	$10	$0.28	+3,536.36%	1	Oct 3, 2023
	IMCR Immunocore Holdings	Initiates: Overweight	$84	$31.93	+163.08%	1	Aug 16, 2023
	DAWN Day One Biopharmaceuticals	Initiates: Overweight	$40	$6.03	+563.35%	1	Feb 8, 2023
	FENC Fennec Pharmaceuticals	Initiates: Overweight	$11	$8.07	+36.31%	1	Sep 7, 2022
	GNTA Genenta Science	Initiates: Buy	$21	$3.75	+460.00%	1	Jan 13, 2022
	KZIA Kazia Therapeutics	Initiates: Buy	$900	$8.24	+10,822.33%	1	Oct 14, 2021

Biomea Fusion

Aug 29, 2024

Initiates: Overweight

Price Target: $25

Current: $1.63

Upside: +1,433.74%

Immutep

May 17, 2024

Initiates: Overweight

Price Target: $10

Current: $1.81

Upside: +452.49%

Erasca

Mar 11, 2024

Initiates: Overweight

Price Target: $8

Current: $1.46

Upside: +447.95%

Carisma Therapeutics

Oct 3, 2023

Initiates: Overweight

Price Target: $10

Current: $0.28

Upside: +3,536.36%

Immunocore Holdings

Aug 16, 2023

Initiates: Overweight

Price Target: $84

Current: $31.93

Upside: +163.08%

Day One Biopharmaceuticals

Feb 8, 2023

Initiates: Overweight

Price Target: $40

Current: $6.03

Upside: +563.35%

Fennec Pharmaceuticals

Sep 7, 2022

Initiates: Overweight

Price Target: $11

Current: $8.07

Upside: +36.31%

Genenta Science

Jan 13, 2022

Initiates: Buy

Price Target: $21

Current: $3.75

Upside: +460.00%

Kazia Therapeutics

Oct 14, 2021

Initiates: Buy

Price Target: $900

Current: $8.24

Upside: +10,822.33%